AEMD earnings analysis
What we found in AEMD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Aethlon reported a $4.02 diluted EPS loss, missing the $3.76 consensus estimate by $0.26, while revenue, margins, cash flow and segment results were not disclosed in the provided filing text. The company remains loss-making and financing-dependent, although management indicated that current resources should fund operations for at least 12 months following approximately $4.0 million raised after quarter-end. The filing reported no material risk-factor changes from the March 31, 2026 Annual Report.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS Missed Consensus
- Aethlon reported a diluted EPS loss of $4.02, versus the $3.76 consensus estimate, a $0.26 miss or approximately 6.9%.
- Controls Remained Effective
- Management concluded that disclosure controls were effective as of June 30, 2026, and reported no changes in internal control over financial reporting during the quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, controls.
- No Material Legal or Equity Actions
- The company reported no material pending legal proceedings and no unregistered securities issuances during the three months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Financing and Dilution Dependence
- The company remains dependent on external financing. It raised approximately $4.0 million after quarter-end, while management said current resources fund operations for at least 12 months, indicating limited visibility beyond that period.
- Ongoing Clinical-Stage Losses
- The $4.02 diluted EPS loss and absence of disclosed revenue reflect continued clinical-stage execution risk and no demonstrated commercial revenue base in the reported period.
- No Material Risk-Factor Improvement
- The filing states there have been no material updates or changes to the risk factors in the Annual Report for the fiscal year ended March 31, 2026; therefore, no new risk mitigation or reduction was disclosed.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-4.02
What they said about what is next.
No formal revenue or EPS guidance was provided. Management stated that current cash resources should fund operations for at least the next 12 months; quantitative outlook was otherwise deferred.
The filing reads worse than the one before it.
What came before.
- 10-K · June 10, 2026
- Aethlon Medical, Inc. disclosed a diluted EPS loss of -10.61 for fiscal year 2026 against an estimate of -2.46, with no revenue generated. The operating expenses decreased by 21.9% year-over-year to approximately $7.3…
- 10-Q · February 12, 2026
- Aethlon Medical, Inc. reported a net loss of approximately $2,018,000 for Q3 2025, a noticeable increase from the prior year's net loss of $1,755,000. The earnings per share came in at a diluted loss of ($2.45),…
- 10-Q · November 12, 2025
- Aethlon Medical, Inc. reported a substantial net loss of $1,487,100 for Q2 2025, a decline in EPS to -$3.74 compared to -$16.11 in Q2 2024, while total revenues remained at $0. The company's operating expenses…
- 10-Q · August 13, 2025
- Aethlon Medical, Inc. reported no revenue for the second quarter of 2025, with a significant diluted EPS loss of -$3.70, reflecting continued financial strain. Operating expenses decreased by 31.6% year-over-year,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AEMD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever